Conditional Approval for the Listing of Noveko International Inc.'s Shares at the Toronto Stock Exchange

    EKO / TSX Venture Exchange

    MONTREAL, July 15 /CNW Telbec/ - Noveko International Inc. (the
"Corporation") is pleased to announce that the Toronto Stock Exchange (the
"TSX") has conditionally approved the listing of its Class A Shares subject to
the Corporation satisfying certain customary filing and other requirements.
    "We are very pleased of this conditional approval. It is a very important
stage in the growth of the Corporation that will provide us a better
visibility and trading liquidity for our shares. We wish, moreover, to express
our thanks to the TSX Venture Exchange and to its personnel with whom we made
our first steps," indicated André Leroux, Chairman and Chief Executive Officer
of the Corporation.
    In order for the Class A Shares to commence trading on the TSX, various
documents will have to be submitted to it at the latest on 12 p.m. (noon)
three business days prior to the listing date. Since the acquisition of SARL
Noveko Algérie and of Groupe Conseils Micron-Air Inc. are scheduled to be
completed by the end of this week, the Corporation expects that trading on the
TSX would commence at the end of next week (ticker symbol: EKO), subject to
compliance with all of the requirements of the TSX, including compliance with
the TSX security based compensation arrangements policy and clearance of all
the officers and directors of the Corporation to TSX satisfaction. The
Corporation will make an application to the TSX Venture Exchange (the "TSXV")
to voluntarily delist its Class A Shares from the TSXV, such delisting to be
effective as of the date the Corporation's Class A Shares begin trading on the


    Noveko International Inc. is a public holding company. Currently, its
operating subsidiaries are S.A.S. ECM, Noveko Inc., Laboratoire SyMa Inc.,
Bolduc Leroux Inc., Magnum Pharmaceutics Inc. and Unitam International
Management Corporation Inc. ECM specializes in portable real-time ultrasound
scanners for veterinary and human medicine. Noveko Inc. develops biomedical
and environmental products derived from its patented antimicrobial filtration
technology (Noveko(TM) antimicrobial face masks and air filters). SyMa
specializes in sanitizers, sold under the Azuro(TM) brand. Magnum acts as a
manufacturer sales agent for the Noveko Group's biomedical and environmental
products and sanitizers and for other manufacturers. Unitam is an
international business development service agency established in North America
and Asia. BLI is involved in the custom processing and distribution of steel
products based on client specifications.

    The information set forth in this press release includes certain
forward-looking statements. Such statements are based on assumptions exposed
to major risks and uncertainties. Although Noveko deems the expectations
reflected in these forward-looking statements to be reasonable, the Company
cannot provide any guarantee as to the materialization of the expectations
reflected in these forward-looking statements. The TSX Venture Exchange and
the Toronto Stock Exchange have not reviewed and do not accept responsibility
for the adequacy or accuracy of this release.

For further information:

For further information: André Leroux, Chairman of the Board and Chief
Executive Officer; Alain Bolduc, President and Chief Operating Officer, Noveko
International Inc., (514) 344-3030,

Organization Profile

Noveko International Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890